Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weekly shot shows promise for blood sugar and weight control in type 1 diabetes

NCT ID NCT05537233

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times

Summary

This study tested a once-weekly medicine called semaglutide in 115 adults with type 1 diabetes and obesity who already use an automated insulin pump. The goal was to see if adding semaglutide helps improve blood sugar control and reduce weight. Participants received either semaglutide or a placebo for 26 weeks, and researchers measured changes in blood sugar levels and body weight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Barbara Davis Center for Diabetes

    Aurora, Colorado, 80045, United States

  • Harold Schnitzer Diabetes Health Center

    Portland, Oregon, 97239, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Iowa Diabetes Research Center

    West Des Moines, Iowa, 50265, United States

Conditions

Explore the condition pages connected to this study.